B1 Marketing Group

Hundreds of Tylenol lawsuits remain revived after an appeals court rejected the defendants’ request for reconsideration. On October 16, the Second Circuit denied a rehearing request from Kenvue and several retailers, leaving its earlier ruling on plaintiffs’ expert testimony in place. That ruling revived lawsuits alleging that prenatal acetaminophen exposure caused autism or ADHD. The underlying appeal concerned whether the trial court improperly excluded expert testimony. The appeals court upheld the exclusion of two experts but rejected the exclusion of three others, returning the cases for further proceedings. This is a procedural development, not a finding that acetaminophen causes autism or ADHD, a liability verdict, or a settlement. The plaintiffs still must prove their claims. #TylenolLitigation #Acetaminophen #ProductLiability #LegalNews #B1Marketing

3M is challenging the legal foundation of Australia’s PFAS lawsuit, which seeks more than $2 billion over contamination at 28 military bases. At an October 16 hearing, 3M’s lawyer argued that Australia’s public nuisance claim does not meet the requirements of Australian law. The company also plans to argue that some consumer-protection claims involving decades-old statements about its firefighting foam are time-barred. These are defense arguments, not court rulings dismissing the case. Australia alleges that 3M failed to adequately warn about the foam’s risks. The government says it has spent approximately $1.3 billion addressing contamination, including $408 million in settlements with affected communities, and is seeking recovery for past and future costs. 3M’s defense is due December 11, and the case is expected to return to court in December. No liability has been established in this proceeding. #PFASLawsuit #3M #ForeverChemicals #EnvironmentalLitigation #B1Marketing

This week in mass tort news brought upcoming trials, a major appellate development, and new details in litigation over AI chatbot safety. From Camp Lejeune trial preparations to Roundup’s latest legal challenge, this week highlighted developments across closely watched mass torts, product liability cases, and platform safety litigation. Here’s a quick recap of the biggest headlines: Camp Lejeune’s first kidney cancer trial is scheduled for October 26, as the court pushes parties toward a global resolution without guaranteeing a settlement. The Supreme Court sent a $28 million Roundup judgment back for reconsideration under its ruling on federal preemption and cancer-warning claims. Bard PowerPort litigation is moving toward additional bellwether trials after an early defense verdict and a $40 million plaintiff award involving different alleged device failures. Kentucky’s newly unredacted Character AI complaint revealed allegations involving chatbot responses to self-harm and suicide, bringing new scrutiny to an existing state enforcement case. Mass tort and product liability litigation continue to move fast, and this week showed why the details behind each headline matter. #MassTort #MassTortNews #LegalNews #LitigationUpdate #B1Marketing

Newly disclosed allegations against Character AI are putting its chatbot safety protections under renewed scrutiny. Kentucky Attorney General Russell Coleman filed an unredacted complaint on October 7, revealing allegations that some chatbot responses encouraged self-harm, starvation, and suicide. The disclosure adds detail to a state enforcement lawsuit originally filed in January. Kentucky alleges that the platform prioritized engagement over children’s well-being and failed to provide adequate safeguards. The filing does not identify every user’s age, although the state alleges that at least some were children. Reuters reported that the circumstances surrounding the cited conversations were unclear. Character AI has previously said it prioritizes user safety, but did not immediately respond to Reuters about the newly disclosed allegations. The claims have not been proven in court. #CharacterAI #AIChildSafety #ArtificialIntelligence #ConsumerProtection #B1Marketing

Bard PowerPort’s fourth federal bellwether trial is set for December 1, following a defense verdict and a $40 million plaintiff award in the first two trials. The upcoming case involves Missouri plaintiff Judy Hicks, who alleges that a PowerPort implanted during breast cancer treatment was associated with a Staph infection and clotting complications. She underwent two procedures to remove the device and remaining components. These allegations have not been decided at trial. More than 4,000 lawsuits are pending in the Arizona MDL, involving allegations of catheter fractures, migration, infections, and other serious complications. The third bellwether was scheduled to begin October 13, with a fifth set for February 2, 2027. A final pretrial conference in Hicks’ case is scheduled for October 26. The bellwethers provide case-specific tests of the evidence, but their verdicts do not automatically determine liability or compensation in the remaining lawsuits. #BardPowerPort #BellwetherTrial #MedicalDeviceLitigation #MassTorts #B1Marketing

The Supreme Court has sent a $28 million Roundup judgment back for reconsideration, showing how an appellate ruling can reshape a case long after a jury verdict. The October 13 action concerns Mike Dennis, who alleged that Roundup caused his mycosis fungoides, a rare form of non-Hodgkin lymphoma. His original $332 million jury award was reduced to $28 million before the case reached the Supreme Court. The central issue now is preemption: whether federal pesticide law prevents a state-law claim from requiring a cancer warning that is absent from the EPA-approved label. In its June decision in Monsanto Co. v. Durnell, the Supreme Court held that it does. The California appeals court must reconsider Dennis’ case under that ruling. This is not a new jury assessment of the cancer evidence, and it should not be described as a final ruling on every possible Roundup claim. What stands out to me is the distinction between evidence and legal viability. A substantial verdict can still face a decisive challenge over whether the underlying claim is permitted by law, making the specific legal theory just as important to watch as the damages figure. #RoundupLawsuit #MassTorts #SupremeCourt #ProductLiability #B1Marketing

The Camp Lejeune litigation is approaching its first trial, with a kidney cancer case scheduled to begin October 26 before U.S. District Judge Terrence W. Boyle. A second kidney cancer bench trial is set for November 9. Because these are bench trials, Judge Boyle, rather than a jury, will decide the evidence, liability, and any damages. The results will not resolve the broader litigation, but they could provide an early signal of how the court evaluates the claims. The parties face an October 16 deadline to submit amended pretrial materials, including narrowed witness and exhibit lists. They also remain under a court-directed October 30 target to use their best efforts toward a broader resolution. No global settlement has been announced. The Department of Justice reports that, as of September 18, settlement offers exceeded $1.1 billion and payouts exceeded $879 million. Those figures reflect the existing settlement process and do not establish the value of every remaining claim. #CampLejeune #WaterContamination #KidneyCancer #MassTort #B1Marketing

This lead looked perfect. It wasn't. The name, injury, and timeline all lined up. On paper, it looked ready to move forward. Then the details told a different story. One phone number tied to multiple “claimants.” An ID that didn’t match. An address that didn’t exist. This is an illustrated example, not a client file, but it reflects a pattern we regularly catch. The problem isn’t whether your intake vendor says a lead is “verified.” It’s what they actually checked. DM ‘AUDIT’ and we’ll review your intake flow to show you where bad claimants slip through. . . . #B1Marketing #IntakeFirewall #MassTort #LawFirmMarketing #LegalMarketing

This week in mass tort and major litigation brought significant verdicts, new federal MDLs, and a settlement ahead of a closely watched bellwether trial. Across these developments, context remained important. Allegations differ from jury findings, and individual case outcomes do not necessarily signal broader litigation trends. Here’s a quick look at the latest headlines: Johnson & Johnson secured a Massachusetts defense verdict after jurors found that Johnson’s Baby Powder did not cause Stephanie Pelley’s mesothelioma, while also finding that the product should have carried a warning. More than 100 riders are represented by counsel over alleged brain injuries associated with Six Flags Magic Mountain’s X2 roller coaster, which the park announced would be permanently retired. Uber reached a confidential settlement before its third federal passenger sexual assault bellwether trial, with approximately 4,900 cases remaining in the MDL. Separate federal MDLs were established for Abbott and Nevro spinal cord stimulators. These proceedings join the existing Boston Scientific litigation while keeping manufacturer-specific claims separate. New Mexico is pursuing up to $40 billion in penalties against Meta following a jury’s findings concerning misleading privacy statements. The judge has not yet determined the penalty. Apple’s AirTag stalking litigation entered a federal MDL, bringing common questions about device design and safety protections into coordinated proceedings. As these cases develop, understanding what was alleged, what was decided, and what remains unresolved is essential to reading beyond the headlines. #MassTort #MassTortNews #LegalNews #LitigationUpdate #B1Marketing

Apple AirTag stalking lawsuits now have a federal MDL, marking a significant new development in the litigation. On October 2, the U.S. Judicial Panel on Multidistrict Litigation centralized the cases in the Northern District of California before Judge Noël Wise. The order identified 17 lawsuits and 12 additional related cases, bringing the litigation to nearly 30 reported federal actions. Plaintiffs allege that AirTags enabled unauthorized tracking and that Apple’s safeguards, including delayed alerts, failed to adequately protect them from stalking and related harm. Apple opposed centralization, arguing that the individual incidents differed too much to benefit from coordinated proceedings. The panel disagreed, finding that common questions about AirTag design, safety features, and potential alternative designs supported creating an MDL. The cases will now move through coordinated discovery and pretrial proceedings. Centralization is a procedural milestone, not a finding of liability or an announced settlement. #AppleAirTag #MassTorts #MDL #ProductLiability #B1Marketing